adebrelimab + SHR-A1904

Adebrelimab + SHR-A1904 is a combination regimen being investigated for the treatment of **CLDN18.2-positive advanced solid tumors**, primarily including **gastric cancer and gastroesophageal junction adenocarcinoma**[1][4][6]. **Adebrelimab** is a **monoclonal antibody** targeting **programmed death-ligand 1 (PD-L1)**, functioning as a **checkpoint inhibitor** to boost antitumor immune responses. **SHR-A1904** is an **antibody-drug conjugate (ADC)** that consists of a **CLDN18.2-targeting monoclonal antibody** conjugated to a **DNA topoisomerase I inhibitor payload** via a **cleavable peptide-based linker**; it delivers cytotoxic activity selectively to CLDN18.2-expressing tumor cells[3][4][5]. The combination aims to synergize immune checkpoint blockade with targeted cytotoxicity for improved antitumor efficacy. Both agents are being developed by **Suzhou Suncadia Biopharmaceuticals** and **Shanghai Hengrui Pharmaceutical** and are undergoing phase Ib/II/III clinical trials for CLDN18.2-positive solid tumors, including but not limited to **gastric cancer and gastroesophageal junction cancer**[1][2][4][5][6][9].

Other names

adebrelimab + SHR-A1904SHR-A1904 + ADEBRELIMAB